IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

Aggregated presentation by day and by market



Statement of transactions in own shares from September 15th to September 19th 2025
       
Name of the issueIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150300118,40AQEU
IPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150600118,40CCXE
IPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150300118,40TQEX
IPSEN549300M6SGDPB4Z94P1115/09/2025FR00102591503400119,279XPAR
IPSEN549300M6SGDPB4Z94P1116/09/2025FR0010259150300117,10AQEU
IPSEN549300M6SGDPB4Z94P1116/09/2025FR0010259150600117,30CCXE
IPSEN549300M6SGDPB4Z94P1116/09/2025FR0010259150300117,20TQEX
IPSEN549300M6SGDPB4Z94P1116/09/2025FR00102591503226117,19544XPAR
IPSEN549300M6SGDPB4Z94P1117/09/2025FR0010259150300115,70AQEU
IPSEN549300M6SGDPB4Z94P1117/09/2025FR0010259150600115,90CCXE
IPSEN549300M6SGDPB4Z94P1117/09/2025FR0010259150300115,63333TQEX
IPSEN549300M6SGDPB4Z94P1117/09/2025FR00102591503299115,75171XPAR
IPSEN549300M6SGDPB4Z94P1118/09/2025FR0010259150192114,46875AQEU
IPSEN549300M6SGDPB4Z94P1118/09/2025FR0010259150600114,80CCXE
IPSEN549300M6SGDPB4Z94P1118/09/2025FR0010259150300114,00TQEX
IPSEN549300M6SGDPB4Z94P1118/09/2025FR00102591503239115,16554XPAR
IPSEN549300M6SGDPB4Z94P1119/09/2025FR0010259150300115,30AQEU
IPSEN549300M6SGDPB4Z94P1119/09/2025FR0010259150600115,60CCXE
IPSEN549300M6SGDPB4Z94P1119/09/2025FR0010259150300115,30TQEX
IPSEN549300M6SGDPB4Z94P1119/09/2025FR00102591503400114,85218XPAR
    22456116,41844 

Attachment



EN
23/09/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from September 15th to September 19th 2025       Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150300118,40AQEUIPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150600118,40CCXEIPSEN549300M6SGDPB4Z94P1115/09/2025FR001...

6h / 1m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2025 Présentation agrégée par jour et par marchéDéclaration des transactions sur actions propres réalisées du 15 Septembre au 19 Septembre 2025       Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150300118,40AQEUIPSEN549300M6SGDPB4Z94P1115/09/2025FR0010259150600118,40CCXEIP...

6h / 1m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, diffe...

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacyData showed a rapid onset of action, peak effect superior to placebo, and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport, defined as a score of “none” or ...

September 22, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil cl...

L’essai de Phase II LANTIC d’Ipsen en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l’étude de Phase III L'IPN10200 est une molécule recombinante, première de sa classe (« first-in-class »), spécifiquement conçue pour obtenir une affinité et une internalisation accrues du récepteur, offrant ainsi une durée d’action prolongée et un profil optimisé en termes de sécurité et d’efficacitéLes données ont démontré un début d'action rapide, un effet maximal supérieur au placebo et une majorité substantiel...

September 22, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults PFIC is a rare and life-threatening liver disease that affects an estimated 100 children and infants in Japan.1 Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) h...

September 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch